Trametinib dimethyl sulfoxide + uprosertib is under clinical development by Novartis and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Trametinib dimethyl sulfoxide + uprosertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trametinib dimethyl sulfoxide + uprosertib overview
Trametinib (GSK-1120212) with uprosertib (GSK-2141795) is under development for the treatment of refractory endometrial cancer and relapsed or refractory multiple myeloma. The combination therapy is administered orally. Trametinib is a mitogen-activated protein kinase-1 /2 (MEK1/2) inhibitor. Uprosertib is a low nanomolar pan-AKT kinase inhibitor. It was under development for cervical cancer, metastatic uveal melanoma, pancreatic cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, relapsed or refractory acute myeloid leukemia, triple negative metastatic breast cancer and melanoma.
Novartis overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Trametinib dimethyl sulfoxide + uprosertib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
